Skip to content

Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)

Epilepsy

The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.

null

Conditions de participation

  • Sexe:

    Male, Female, Intersex

  • Âges admissibles:

    0 to 17

Critères de participation

Inclusion Criteria:
Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency
Exclusion Criteria:
Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB22-0797